Zobrazeno 31 - 40
of 117
pro vyhledávání: ''
Autor:
Charles W. Riggs, Dan L. Longo, William E. Fogler, John W. Pearson, Hirotsugu Watabe, Kirk Volker, Robert H. Wiltrout, Keiko Ariyoshi
Publikováno v:
JNCI Journal of the National Cancer Institute. 87:94-103
BACKGROUND The anti-P-glycoprotein monoclonal antibody MRK-16 mediates the reversal of multidrug resistance. Recombinant human interferon alfa (rHuIFN alpha) enhances the cytotoxic activity of diverse chemotherapeutics and may modulate multidrug resi
Publikováno v:
JNCI Journal of the National Cancer Institute. 95:1099-1101
Although small-cell lung cancer (SCLC) once constituted 20%–25% of all newly diagnosed lung cancers in North America, in recent years the incidence has decreased to less than 15% (1,2). Nonetheless, deaths resulting from SCLC remain substantial and
Publikováno v:
JNCI Journal of the National Cancer Institute. 86:1534-1539
BACKGROUND Adjuvant tamoxifen therapy for breast cancer has been given for a period of several years. Cardiovascular diseases increased in incidence rapidly in women older than 60 years. Favorable changes in cardiovascular risk factors have been seen
Autor:
Rachel Tsan, Corazon D. Bucana, Isaiah J. Fidler, Robert Radinsky, Dominic Fan, Zhongyun Dong, Christoph Wilmanns
Publikováno v:
JNCI Journal of the National Cancer Institute. 86:913-920
BACKGROUND The major cause of death from cancer is metastases that are resistant to conventional therapies. The resistance of metastatic tumor cells to chemotherapy can be caused by their intrinsic properties, such as increased expression of the mdr
Autor:
Anne Tompkins, William D. Figg, Oliver Sartor, Alain Thibault, M. Weinberger, Michael R. Cooper, Seth M. Steinberg, Charles E. Myers, Donna Headlee, W M Linehan
Publikováno v:
JNCI Journal of the National Cancer Institute. 86:222-227
Background The best treatment for patients with "hormone-refractory" metastatic prostate cancer is unclear, particularly in patients for whom suramin and hydrocortisone have failed. Purpose We investigated a combination of flutamide withdrawal and am
Autor:
George J. Bosl, Vaia Vlamis, Dean F. Bajorin, Madhu Mazumdar, Subhash C. Gulati, Robert J. Motzer, P Lyn
Publikováno v:
JNCI Journal of the National Cancer Institute. 85:1828-1835
BACKGROUND Between 20% and 30% of patients with advanced germ cell tumors (GCTs) fail to have durable complete response to conventional cisplatin-based induction chemotherapy. However, third-line therapy with high-dose carboplatin and etoposide plus
Publikováno v:
JNCI Journal of the National Cancer Institute. 85:1412-1418
BACKGROUND Antiestrogens inhibit the stimulative effects of estrogens on breast cancer growth, but the mechanism(s) by which they trigger tumor regression are not completely understood. Growth retardation and tumor regression can be achieved by enhan
Publikováno v:
JNCI Journal of the National Cancer Institute. 85:806-812
Background The nonsteroidal anti-estrogen tamoxifen (TAM) is the front-line endocrine treatment for breast cancer, but disease recurrence is common. Treatment failure may occur because tumors become insensitive to TAM. Alternatively, resistance may o
Autor:
Ruth M. Heyn, Farced M. Khan, Malcolm A. Smith, Richard S. Ungerleider, Lorraine Cazenave, Edmund A. Gehan, Larry Rubinstein, Harold M. Maurer
Publikováno v:
JNCI Journal of the National Cancer Institute. 85:554-558
Background Recent reports have documented the occurrence of treatment-related acute myeloid leukemia (AML) following therapy with epipodophyllotoxins. These reports have led to growing concern among oncologists, which could lead to premature abandonm
Autor:
George J. Bosl, Robert J. Motzer
Publikováno v:
JNCI Journal of the National Cancer Institute. 84:1703-1709
A review of the published literature shows that treatment with high-dose carboplatin and etoposide with autologous bone marrow transplantation results in durable complete responses (3-42 months, continuous at time of report) in about 10%-20% of heavi